 The primary outcome is MTD, defined as the maximum dose that produces dose-limiting toxicity DLT in at most 2 out of the 6 participants. Secondary outcomes include patient-reported outcomes, objective clinical and imaging assessments at 32mg and 64mg, and pharmacokinetics. 